Effect of Gammalinolenic acid in hand eczema

Comparison of therapeutic effect of topical GAMMANOL cream- contains 6% gamma linolenic acid- with mometasone 0/1% cream in hand eczema by two scoring systems of DLQI and HECSI in patients with chronic or subacute hand eczema

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201101049215N1

Enrollment

Registered

2020-11-22

Start date

2019-11-22

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hand eczema. Disease of the skin and subcutaneous tissue

Interventions

Intervention 1: Intervention group: 26 patients with chronic and subacute hand eczema who receive Gammanol cream containing 6% gammalinolenic acid, manufactured by Asacpharma company, at the rate of 3

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Chronic or subacute hand eczema, unilateral or bilateral

Exclusion criteria

Exclusion criteria: Acute hand eczema pregnant or lactating women Use systemic immunosuppressant drug for one recent month Use topical therapies for hand eczema for two recent weeks To have localized infection in hands

Design outcomes

Primary

Measure	Time frame
Han Eczema Severity Score and Dermatology Life Quality Score. Timepoint: First visit and after one month of drug use. Method of measurement: measurement table of hand eczema severity index and questionnaire of dermatologiy life quality index.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarideh Jokar

Shiraz University of Medical Sciences

nedazakeri@yahoo.com+98 71 3212 5239

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026